11-beta-Hydroxysteroid Dehydrogenase Type 2 (11 beta-Hydroxysteroid Dehydrogenase Type 2)

Subscribe to Selected New Research on 11-beta-Hydroxysteroid Dehydrogenase Type 2

165 relevant articles (1 outcomes, 19 trials/studies) found for this Bio-Agent

Description: An high-affinity, NAD-dependent 11-beta-hydroxysteroid dehydrogenase that acts unidirectionally to catalyze the dehydrogenation of CORTISOL to CORTISONE. It is found predominantly in mineralocorticoid target tissues such as the KIDNEY; COLON; SWEAT GLANDS; and the PLACENTA. Absence of the enzyme leads to a fatal form of childhood hypertension termed, APPARENT MINERALOCORTICOID EXCESS SYNDROME.

Also Known As:

11 beta-Hydroxysteroid Dehydrogenase Type 2; 11 beta-HSD2; 11beta-HSD2; 11beta-HSD2 Reductase; 11beta-Hydroxysteroid Dehydrogenase Type 2; 11 beta Hydroxysteroid Dehydrogenase Type 2; 11beta Hydroxysteroid Dehydrogenase Type 2

Relationship Network

Bio-Agent Context: Research Results

Enzymes and Coenzymes: 1

Enzymes: 24340

Oxidoreductases: 6825

Alcohol Oxidoreductases

Hydroxysteroid Dehydrogenases: 6

11-beta-Hydroxysteroid Dehydrogenases: 219

11-beta-Hydroxysteroid Dehydrogenase Type 2: 165

human HSD11B2 protein

Experts

1.	Sasano, Hironobu: 5 articles (01/2005 - 11/2002)
2.	Suzuki, Takashi: 5 articles (01/2005 - 11/2002)
3.	Mune, Tomoatsu: 3 articles (05/2006 - 11/2002)
4.	Frey, F J: 3 articles (03/2001 - 03/2000)
5.	Ferrari, P: 3 articles (03/2001 - 03/2000)
6.	Hardy, D B: 2 articles (08/2006 - 08/2002)
7.	Yang, K: 2 articles (08/2006 - 08/2002)
8.	Murphy, Vanessa E: 2 articles (04/2006 - 04/2002)
9.	Clifton, Vicki L: 2 articles (04/2006 - 04/2002)
10.	Stewart, Paul M: 2 articles (08/2005 - 04/2002)

Related Diseases

1.	Hypertension (High Blood Pressure) 04/01/1999 - "Finally, while some studies demonstrate impaired 11beta-HSD activity in broader populations of patients with hypertension, further studies are required to clarify the role of 11beta-HSD2 in 'essential' hypertension." 12/01/1997 - "Further studies are now required in order to evaluate the role of 11beta-HSD2 activity in the pathophysiology of 'essential' hypertension." 06/01/2008 - "CONCLUSION: Reduced 11beta-HSD2 activity emerges as a previously unrecognized risk factor contributing to the rising prevalence of arterial hypertension in elderly" 03/01/2008 - "It is well established that reduced 11beta-HSD2 activity causes hypertension and electrolyte abnormalities" 11/01/2007 - "Reduced activity of 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) plays a role in essential hypertension and the sensitivity of blood pressure to dietary salt" Get all the results and reference details, order at left...
2.	Fetal Growth Retardation (Intrauterine Growth Retardation) 04/01/2000 - "In humans, 11beta-HSD2 gene mutations produce a low birthweight, and some studies show reduced placental 11beta-HSD2 activity in association with intrauterine growth retardation" 02/01/2008 - "Taken together, our present findings provide evidence suggesting a role for an attenuated placental as well as fetal 11beta-HSD2 in the pathogenesis of IUGR." 02/01/2008 - "There is evidence that placental 11beta-HSD2 is reduced in pregnancies complicated with intrauterine growth restriction (IUGR), but the relationship between the two is uncertain owing to other maternal complications often associated with this pathological condition of pregnancy" 09/01/2005 - "Decreased 11beta-HSD2 activity has been suggested for a reason to IUGR and to its metabolic consequences" 12/01/2004 - "In humans, 11beta-HSD2 gene mutations cause low birth weight and reduced placental 11beta-HSD2 activity associated with intrauterine growth retardation" Get all the results and reference details, order at left...
3.	Anoxia (Hypoxia) 04/01/2007 - "Shallow trophoblast invasion with the resulting hypoxemia seems to critically reduce available 11beta-HSD2 activity" 08/01/2006 - "As demonstrated previously, hypoxia blocked the increase in levels of both 11beta-HSD2 activity and protein within the first 24h" 08/01/2006 - "Hypoxia blocks 11beta-hydroxysteroid dehydrogenase type 2 induction in human trophoblast cells during differentiation by a time-dependent mechanism that involves both translation and transcription." 05/01/2003 - "Thus, hypoxia decreases 11beta-HSD2 transcription and activity by inducing Egr-1 in vivo and in vitro" 05/01/2003 - "The early growth response gene, Egr-1, a gene known to be stimulated by hypoxia was investigated because of a potential Egr-1 binding site in the promoter region of 11beta-HSD2" Get all the results and reference details, order at left...
4.	Choriocarcinoma 09/01/2003 - "METHODS: The human choriocarcinoma cell line JEG-3, which expresses the 11beta-HSD2 isoenzyme, was used" 04/01/1995 - "11 alpha-OHP and 11 beta-OHP were potent inhibitors of both 11 beta-HSD1 in rat liver microsomes and 11 beta-HSD2 in lysates of JEG-3 cells, a human choriocarcinoma cell line" 07/01/1999 - "In the present study, we examined the effects of eicosanoids on the activity of 11beta-HSD2 in human choriocarcinoma JEG-3 cells, a well-established model for placental trophoblasts" 07/01/2005 - "Effect of pro-inflammatory cytokines on expression and activity of 11beta-hydroxysteroid dehydrogenase type 2 in cultured human term placental trophoblast and human choriocarcinoma JEG-3 cells." 03/01/1999 - "Retinoic acid stimulates the expression of 11beta-hydroxysteroid dehydrogenase type 2 in human choriocarcinoma JEG-3 cells." Get all the results and reference details, order at left...
5.	Neoplasms (Cancer) 06/01/2008 - "Our study indicates MR and 11beta-HSD2 are both sensitive and specific markers of the distal nephron and its related neoplasms (CHRCC and OC)" 06/01/2008 - "MR and 11beta-HSD2 should be considered in the immunohistochemical panel to more accurately subtype renal cell tumors." 06/01/2008 - "Our goal was to determine whether MR and 11beta-HSD2 expression could be used to characterize the major types of renal cell neoplasms" 02/12/2004 - "The finding that 11-ketoDex is a specific GR agonist may explain the potent glucocorticoid effect of Dex in tissues expressing 11beta-HSD2 including kidney and colon and also in certain tumor cells." 03/20/2003 - "We propose that abnormal expression of 11 beta-HSD2 acts as a proproliferative prereceptor determinant of pituitary cell growth, and may provide a novel target for future tumor therapy." Get all the results and reference details, order at left...
67 Diseases and 165 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Sodium
2.	11-beta-Hydroxysteroid Dehydrogenase Type 1
3.	Hormones
4.	Enzymes
5.	Hydrocortisone (Cortisol)
6.	Messenger RNA (mRNA)
7.	Mineralocorticoid Receptors (Mineralocorticoid Receptor)
8.	11-beta-Hydroxysteroid Dehydrogenase Type 2 (11 beta-Hydroxysteroid Dehydrogenase Type 2)
9.	Cortisone
10.	Corticosterone
76 Drugs and Important Bio-Agents and 115 more articles analyzed in the Research Interface, order at left...

Related Therapies and Procedures

1.	Ligation
2.	Colectomy
2 Therapies and Procedures and 2 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>